Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors

E-ISSN： 1876-1038|5|2|117-122

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.5, Iss.2, 2010-05, pp. : 117-122

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara Cho Daniel C

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite

Management of chronic lymphocytic leukemia (CLL) in the era of B‐cell receptor signal transduction inhibitors

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 657-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma

Oncology Research and Treatment, Vol. 30, Iss. 10, 2007-09 ,pp. : 519-524

Karger

Access to resources Recommend Favorite

Signal Transduction Therapy with Rationally Designed Kinase Inhibitors

Current Signal Transduction Therapy, Vol. 1, Iss. 1, 2006-01 ,pp. : 67-95

Bentham Science Publishers

Access to resources Recommend Favorite

Spontaneous Regression of Hepatic Metastases after Nephrectomy and Metastasectomy of Renal Cell Carcinoma

Urologia Internationalis, Vol. 66, Iss. 2, 2001-02 ,pp. : 119-120

Karger

Access to resources Recommend Favorite